$IVDA
Iveda Solutions, Inc. Stock $ivda

$ivda Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010283 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$2.205M	$2.119M	$4.468M
YoY Change	855.2%	245.58%	132.98%
Cost Of Revenue	$1.718M	$1.839M	$3.505M
YoY Change	1802.88%	505.59%	222.85%
Gross Profit	$486.7K	$279.6K	$963.5K
YoY Change	246.26%	-9.63%	15.77%
Gross Profit Margin	22.07%	13.2%	21.56%
Selling, General & Admin	$1.038M	$1.222M	$4.293M
YoY Change	30.99%	-19.38%	20.67%
% of Gross Profit	213.21%	436.96%	445.54%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$5.030K	$4.660K	$17.80K
YoY Change	7.94%	-318.78%	18.55%
% of Gross Profit	1.03%	1.67%	1.85%
Operating Expenses	$1.038M	$1.222M	$4.293M
YoY Change	30.99%	-19.38%	20.67%
Operating Profit	-$551.0K	-$942.2K	-$3.329M
YoY Change	-15.45%	-21.88%	22.16%
Interest Expense	$517.00	$12.74K	$53.32K
YoY Change	-104.23%	-175.7%	-119.51%
% of Operating Profit
Other Income/Expense, Net	$19.40K	-$17.50K	-$13.00K
YoY Change	11310.59%	-25100.0%
Pretax Income	-$531.6K	-$947.0K	-$3.342M
YoY Change	-19.9%	-22.56%	11.46%
Income Tax	$18.70K	-$50.00	$2.947K
% Of Pretax Income
Net Earnings	-$550.3K	-$946.9K	-$3.345M
YoY Change	-17.48%	-22.57%	11.56%
Net Earnings / Revenue	-24.95%	-44.69%	-74.87%
Basic Earnings Per Share	-$0.04		-$0.26
Diluted Earnings Per Share	-$0.04	-$0.06	-$0.26
COMMON SHARES
Basic Shares Outstanding	16.01M shares	14.97M shares	12.85M shares
Diluted Shares Outstanding	15.29M shares		12.84M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.380M	$7.312M	$7.312M
YoY Change	1021.91%	427.84%	427.84%
Cash & Equivalents	$8.380M	$7.312M	$7.312M
Short-Term Investments
Other Short-Term Assets	$162.5K	$372.0K	$501.5K
YoY Change	-49.93%	19.74%	10.63%
Inventory	$388.2K	$526.5K	$526.5K
Prepaid Expenses
Receivables	$505.6K	$1.223M	$1.223M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.566M	$9.563M	$9.563M
YoY Change	433.13%	257.35%	257.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$204.5K	$32.91K	$32.91K
YoY Change	442.34%	-13.82%	-13.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$288.6K	$267.4K	$267.4K
YoY Change	12.49%	-2.21%	-2.21%
Total Long-Term Assets	$493.1K	$300.3K	$300.3K
YoY Change	67.58%	-3.63%	-3.63%
TOTAL ASSETS
Total Short-Term Assets	$9.566M	$9.563M	$9.563M
Total Long-Term Assets	$493.1K	$300.3K	$300.3K
Total Assets	$10.06M	$9.863M	$9.863M
YoY Change	381.63%	230.13%	230.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$478.1K	$360.4K	$360.4K
YoY Change	-84.02%	473.07%	473.06%
Accrued Expenses	$789.2K	$1.243M	$1.243M
YoY Change		-56.15%	-56.15%
Deferred Revenue
YoY Change
Short-Term Debt	$163.7K	$398.4K	$398.4K
YoY Change	-27.11%	696.82%	696.82%
Long-Term Debt Due	$65.50K	$65.41K	$65.41K
YoY Change	-43.74%	-45.62%	-45.62%
Total Short-Term Liabilities	$1.543M	$2.103M	$2.103M
YoY Change	-57.54%	-38.63%	-38.63%
LONG-TERM LIABILITIES
Long-Term Debt	$174.7K	$190.8K	$190.8K
YoY Change	-41.55%	-43.69%	-43.69%
Other Long-Term Liabilities			$0.00
YoY Change
Total Long-Term Liabilities	$174.7K	$190.8K	$190.8K
YoY Change	-41.55%	-43.69%	-43.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.543M	$2.103M	$2.103M
Total Long-Term Liabilities	$174.7K	$190.8K	$190.8K
Total Liabilities	$1.717M	$2.293M	$2.293M
YoY Change	-56.32%	-39.09%	-39.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$45.26M	-$44.71M
YoY Change		8.09%
Common Stock	$159.00	$150.00
YoY Change		54.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.342M	$7.570M	$7.570M
YoY Change
Total Liabilities & Shareholders Equity	$10.06M	$9.863M	$9.863M
YoY Change	381.63%	230.13%	230.13%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$550.3K	-$946.9K	-$3.345M
YoY Change	-17.48%	-22.57%	11.56%
Depreciation, Depletion And Amortization	$5.030K	$4.660K	$17.80K
YoY Change	7.94%	-318.78%	18.55%
Cash From Operating Activities	$172.6K	-$2.113M	-$5.409M
YoY Change	-122.4%	166.59%	174.26%
INVESTING ACTIVITIES
Capital Expenditures	$176.2K	$8.990K	$14.17K
YoY Change	-3848.0%	-225.56%	-157.79%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$176.2K	-$8.990K	-$14.17K
YoY Change	3648.0%	25.56%	-42.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$11.51M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.072M	-1.181M	$11.41M
YoY Change	636.59%	-222.45%	265.28%
NET CHANGE
Cash From Operating Activities	$172.6K	-2.113M	-$5.409M
Cash From Investing Activities	-$176.2K	-8.990K	-$14.17K
Cash From Financing Activities	$1.072M	-1.181M	$11.41M
Net Change In Cash	$1.068M	-3.302M	$5.927M
YoY Change	-269.65%	-2103.54%	426.36%
FREE CASH FLOW
Cash From Operating Activities	$172.6K	-$2.113M	-$5.409M
Capital Expenditures	$176.2K	$8.990K	$14.17K
Free Cash Flow	-$3.593K	-$2.122M	-$5.423M
YoY Change	-99.53%	170.17%	178.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001397183
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022Q4	IVDA	Long Term Dividend Payable LongTermDividendPayable		usd
CY2021	IVDA	Miscellaneous Income Expense MiscellaneousIncomeExpense		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	IVDA	Interest Value Of Convertible Debt Issued InterestValueOfConvertibleDebtIssued		usd
CY2022	IVDA	Common Stock Warrants Issued For Interest Value CommonStockWarrantsIssuedForInterestValue		usd
CY2021	IVDA	Issuance Of Stock Issued For Services IssuanceOfStockIssuedForServices		usd
CY2022	IVDA	Payments For Proceeds From Financing And Stock Issuance Costs PaymentsForProceedsFromFinancingAndStockIssuanceCosts		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Notes Issued1 NotesIssued1		usd
CY2022	IVDA	Debenture Accrued Interest Converted To Common Stock DebentureAccruedInterestConvertedToCommonStock		usd
CY2022	IVDA	Rent Accounts Payable To Related Party Converted To Common Stock RentAccountsPayableToRelatedPartyConvertedToCommonStock		usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	IVDA	Dividends Paid With Series B Preferred Stock DividendsPaidWithSeriesBPreferredStock		usd
CY2021	IVDA	Dividends Paid With Series B Preferred Stock DividendsPaidWithSeriesBPreferredStock		usd
CY2022	IVDA	Accrued Dividends Converted To Common Stock AccruedDividendsConvertedToCommonStock		usd
CY2022Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent		usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2022Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent		usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards		usd
CY2021Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41345
CY2022	dei	Entity Registrant Name EntityRegistrantName	IVEDA SOLUTIONS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2222203
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1744 S Val Vista
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 213
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Mesa
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85204
CY2022	dei	City Area Code CityAreaCode	(480)
CY2022	dei	Local Phone Number LocalPhoneNumber	307-8700
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	22000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16012639	shares
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7312095	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1385275	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	129527	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	142688	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1222690	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	492752	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	526470	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	344654	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	371990	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	310657	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9562772	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2676026	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32911	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38189	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	267387	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	273419	usd
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	267387	usd
CY2021Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	273419	usd
CY2022Q4	us-gaap	Assets Assets	9863070	usd
CY2021Q4	us-gaap	Assets Assets	2987634	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1638727	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2955826	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	300000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	398409	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	50000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	65408	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	120284	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2102544	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3426110	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	190776	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	338803	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15066739	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15066739	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9668369	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9668369	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	150	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	97	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52496914	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40727518	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-220643	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-143493	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44706671	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41361401	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7569750	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-777279	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9863070	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2987634	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4468279	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1917848	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3504778	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1085593	usd
CY2022	us-gaap	Gross Profit GrossProfit	963501	usd
CY2021	us-gaap	Gross Profit GrossProfit	832255	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4292820	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3557603	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4292820	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3557603	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3329320	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2725349	usd
CY2022	IVDA	Miscellaneous Income Expense MiscellaneousIncomeExpense	-17078	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	57397	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	354	usd
CY2022	us-gaap	Interest Expense InterestExpense	53323	usd
CY2021	us-gaap	Interest Expense InterestExpense	273649	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13004	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-273295	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3342324	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2998644	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2947	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3345270	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2998644	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12846848	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8940367	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-3706568	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2662000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-2091101	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	801908	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	99789	usd
CY2021	IVDA	Stock Issued During Period Value Common Stock For Costs Of Financing StockIssuedDuringPeriodValueCommonStockForCostsOfFinancing	1932736	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	148480	usd
CY2021	IVDA	Adjustments To Additional Paid In Capital Warrants For Interest Expense AdjustmentsToAdditionalPaidInCapitalWarrantsForInterestExpense	69729	usd
CY2021	IVDA	Adjustments To Additional Paid In Capital Convertible Debenture Valuation AdjustmentsToAdditionalPaidInCapitalConvertibleDebentureValuation	69729	usd
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	23750	usd
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	432176	usd
CY2021	IVDA	Additional Paid In Capital Accumulated Deficit Dividends Preferred Stock Stock AdditionalPaidInCapitalAccumulatedDeficitDividendsPreferredStockStock	-40301	usd
CY2021	IVDA	Stock Issued During Period Value Conversion Of Convertible Securities Interest To Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesInterestToCommonStock	1294580	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	514697	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2998644	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9761	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-777279	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-777279	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-1163918	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	120581	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	219900	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5555	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8011250	usd
CY2022	IVDA	Common Stock And Prefunded Warrant Offering CommonStockAndPrefundedWarrantOffering	4999836	usd
CY2022	IVDA	Adjustments To Additional Paid In Capital Warrants Sold In Over Allotment AdjustmentsToAdditionalPaidInCapitalWarrantsSoldInOverAllotment	2797	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3345270	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-77150	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7569750	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7569750	usd
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-8
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3345270	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2998644	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17801	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15016	usd
CY2021	IVDA	Interest Value Of Convertible Debt Issued InterestValueOfConvertibleDebtIssued	69729	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	120581	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	801908	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	5555	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	148480	usd
CY2021	IVDA	Common Stock Warrants Issued For Interest Value CommonStockWarrantsIssuedForInterestValue	69729	usd
CY2022	IVDA	Issuance Of Stock Issued For Services IssuanceOfStockIssuedForServices	219900	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	785969	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	266138	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	214898	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	122786	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	168122	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	100228	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	19919	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	41795	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-1238379	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	452636	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5408720	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1972093	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14165	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24513	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14165	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24513	usd
CY2022	IVDA	Proceeds From Repayments Of Changes In Restricted Cash ProceedsFromRepaymentsOfChangesInRestrictedCash	-214	usd
CY2021	IVDA	Proceeds From Repayments Of Changes In Restricted Cash ProceedsFromRepaymentsOfChangesInRestrictedCash	22457	usd
CY2022	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	358888	usd
CY2021	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-11238	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-300000	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-82711	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-164093	usd
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	459087	usd
CY2021	IVDA	Payments For Proceeds From Financing And Stock Issuance Costs PaymentsForProceedsFromFinancingAndStockIssuanceCosts	88328	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11511741	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2823332	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11406322	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3122599	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-56617	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9761	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5926820	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1135754	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1385275	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	249521	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7312095	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1385275	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	337573	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2565	usd
CY2021	us-gaap	Notes Issued1 NotesIssued1	934750	usd
CY2021	IVDA	Debenture Accrued Interest Converted To Common Stock DebentureAccruedInterestConvertedToCommonStock	359831	usd
CY2021	IVDA	Rent Accounts Payable To Related Party Converted To Common Stock RentAccountsPayableToRelatedPartyConvertedToCommonStock	55789	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	44000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	1932736	usd
CY2021	IVDA	Accrued Dividends Converted To Common Stock AccruedDividendsConvertedToCommonStock	455926	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_z2qGlev7Kcdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zqTkEqMhi1Q3">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zDCbkMG9yXx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_869_zB0qjlSW53ja">Concentrations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash and cash equivalents and trade accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially all cash is deposited in three financial institutions, two in the United States and one in Taiwan. At times, amounts on deposit in the United States may be in excess of the FDIC insurance limit. Deposits in Taiwan financial institutions are insured by CDIC (Central</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit Insurance Corporation) with maximum coverage of NTD <span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_pn6n6_uNTD_c20221231_zZFbXdrn1k93" title="FDIC insurance limit">3</span> million. At times, amounts on deposit in Taiwan may be in excess of the CDIC Insurance limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivables are unsecured, and we are at risk to the extent such amount becomes uncollectible. We perform periodic credit evaluations of our customers’ financial condition and generally do not require collateral. At December 31, 2022 one customer out of a total of 36 customer accounts receivable accounts was <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ChunghwaTelecomMember_zEDd9JhVzJP" title="Concentration risk, percentage">52</span>% of the total accounts receivable. This specific customer was Chicony Power Technology Co Ltd. One customer (Chunghwa Telecom) represented approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zdLdKM6ife3j" title="Percentage of concentration risk">95</span>% of total accounts receivable of $<span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20211231__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zkAYBhU0Qxm5" title="Account receivable">492,752</span> as of December 31, 2021. These customers are longtime customers, and we don’t expect any problem with collectability of these accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from two customers out of 42 total customers represented approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z7W2vNhRGcCk" title="Concentration risk, percentage">52</span>% of total revenue for the year ended December 31, 2022. These specific customers were 1) We had $9<span id="xdx_90E_eus-gaap--Revenues_pdp0_c20220101__20221231__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zsCxbdCKMKE" title="Revenues">48,592</span> revenues (<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_z5pDcQ24fmnb" title="Concentration risk, percentage">21</span>%) from Chunghwa Telecom, 2) We had $<span id="xdx_901_eus-gaap--Revenues_c20220101__20221231__dei--LegalEntityAxis__custom--ChiconyPowerTechnologyCoLtdMember_z2tGu8b6LLI4" title="Revenues">1,385,026</span> revenues (<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChiconyPowerTechnologyMember_zsxyGlUS9Qci" title="Concentration risk, percentage">31</span>%) from Chicony Power Technology Co Ltd, (both Taiwan companies) of total revenues of $<span id="xdx_904_eus-gaap--Revenues_c20220101__20221231_zmWZcCCwZsH5" title="Revenues">4,468,279</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We had revenue from two customers with greater than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--RangeAxis__srt--MinimumMember_zqdd6gqryedc">10</span>% of total revenues for the year ended December 31, 2021 that represented approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zUYWYHAM96Fd" title="Concentration risk, percentage">55</span>% of total revenues. We had $<span id="xdx_90D_eus-gaap--Revenues_c20210101__20211231__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zBLwJtuDWNG7" title="Revenues">786,686</span> revenues (<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_zMUsP9pDuaR1" title="Concentration risk, percentage">41</span>%) from Chunghwa Telecom and $<span id="xdx_902_eus-gaap--Revenues_c20210101__20211231__dei--LegalEntityAxis__custom--TaiwanStockExchangeCorporationMember_z2Nh5CU67yb4" title="Revenues">260,946</span> revenues (<span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--TaiwanStockExchangeCorporationMember_zs9EOdg2r3K7" title="Concentration risk, percentage">14</span>%) from Taiwan Stock Exchange Corporation of total revenues of $<span id="xdx_90F_eus-gaap--Revenues_c20210101__20211231_zQb8dg4u8oUh" title="Revenues">1,917,848</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No other customers represented greater than <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zXj9g8H4lW24" title="Percentage of concentration risk"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zohGR441BL55" title="Percentage of concentration risk">10</span></span>% of total revenues in years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	3000000
CY2022	us-gaap	Revenues Revenues	4468279	usd
CY2021	us-gaap	Revenues Revenues	1917848	usd
CY2022Q4	IVDA	Uncollectible Accounts UncollectibleAccounts	0	usd
CY2021Q4	IVDA	Uncollectible Accounts UncollectibleAccounts	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2022	us-gaap	Depreciation Depreciation	17801	usd
CY2021	us-gaap	Depreciation Depreciation	15016	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	360395	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	62889	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1243027	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2834726	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35305	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58211	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1638727	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2955826	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	120581	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	801908	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z68tDUAp9rMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_z3EDJ4M4lzJg">Reclassification</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in 2021 have been reclassified to conform to the 2022 presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	300000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	300000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	398409	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	50000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	65408	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	120284	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	190776	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	338803	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of the stockholders of our company
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	93887	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	893438	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.80
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	952025	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.76
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	233125	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.26
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	141875	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.76
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.72
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	62500	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	112125	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.44
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	137963	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.44
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1014438	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.80
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.80
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	959750	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.80
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	891563	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.80
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0.32
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	17.76
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1014038	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	5.61
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	959750	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.61
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0100	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0100	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	872259	shares
CY2021Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	543754	shares
CY2020Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5616224	shares
CY2022	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice	2.96
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	509732	shares
CY2021	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice	2.96
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	8214	shares
CY2022	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice	2.80
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	78102	shares
CY2021	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice	2.80
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	246609	shares
CY2022	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited Cancelled Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedCancelledWeightedAverageExercisePrice	2.80
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	103125	shares
CY2021	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited Cancelled Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedCancelledWeightedAverageExercisePrice	2.80
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6233660	shares
CY2022Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.66
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	872259	shares
CY2021Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2022Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	6233660	shares
CY2022Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	2.66
CY2021Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	872259	shares
CY2021Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	3.04
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	11800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	10800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11800000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10800000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3000000	usd
CY2022	IVDA	Year Of Expiration YearOfExpiration	2042
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1000000	usd
CY2021	IVDA	Year Of Expiration YearOfExpiration	2041
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	590000	usd
CY2020	IVDA	Year Of Expiration YearOfExpiration	2040
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	260000	usd
CY2019	IVDA	Year Of Expiration YearOfExpiration	2039
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	160000	usd
CY2018	IVDA	Year Of Expiration YearOfExpiration	2038
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	140000	usd
CY2017	IVDA	Year Of Expiration YearOfExpiration	2037
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1640000	usd
CY2016	IVDA	Year Of Expiration YearOfExpiration	2036
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3400000	usd
CY2015	IVDA	Year Of Expiration YearOfExpiration	2035
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5230000	usd
CY2014	IVDA	Year Of Expiration YearOfExpiration	2034
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5600000	usd
CY2013	IVDA	Year Of Expiration YearOfExpiration	2033
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2850000	usd
CY2012	IVDA	Year Of Expiration YearOfExpiration	2032
CY2011Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2427000	usd
CY2011	IVDA	Year Of Expiration YearOfExpiration	2031
CY2010Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1799000	usd
CY2010	IVDA	Year Of Expiration YearOfExpiration	2030
CY2009Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1750000	usd
CY2009	IVDA	Year Of Expiration YearOfExpiration	2029
CY2008Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1308000	usd
CY2008	IVDA	Year Of Expiration YearOfExpiration	2028
CY2007Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	429000	usd
CY2007	IVDA	Year Of Expiration YearOfExpiration	2027
CY2006Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	476000	usd
CY2006	IVDA	Year Of Expiration YearOfExpiration	2026
CY2005Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	414000	usd
CY2005	IVDA	Year Of Expiration YearOfExpiration	2025
CY2022	IVDA	Taiwan Corporate Tax Rate TaiwanCorporateTaxRate	Sole-Vision Technologies, Inc. is a subsidiary of the Company which is operating in Taiwan as a profit-seeking enterprise. Its applicable corporate income tax rate is 17%. In addition, Taiwan’s corporate tax system allows the government to levy a 10% profit retention tax on undistributed earnings for the prior year. This tax will not be provided if the company distributed the earnings before the ended of the fiscal year
CY2022	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	90000	usd
CY2021	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	1367862	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3345270	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2998644	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12840598	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8940368	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34

Files In Submission

Name	View Source	Status
0001493152-23-010283-index-headers.html	Edgar Link	pending
0001493152-23-010283-index.html	Edgar Link	pending
0001493152-23-010283.txt	Edgar Link	pending
0001493152-23-010283-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
ivda-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
ivda-20221231_lab.xml	Edgar Link	unprocessable
ivda-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
ivda-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ivda-20221231_cal.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IVDA
Iveda Solutions, Inc. Stock $ivda

2023 Q1 Form 10-K Financial Statement

#000149315223010283 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVDA Iveda Solutions, Inc. Stock $ivda

2023 Q1 Form 10-K Financial Statement

#000149315223010283 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVDA
Iveda Solutions, Inc. Stock $ivda